Rating
In
general,
rating
is
an
in
depth
analysis
and
evaluation
in
terms
of
quality
and
quantity.
SciXess
attaches
great
importance
on
performing
their
analyses
-
independently
whether
it
is
a
matter
of
a
company
or
a
technology
rating
-
unexceptionally
under
quantitative
and
qualitative
aspects
.
We
strongly
believe
that
company
and
technology
valuation
is
more
than
just
attaching
a
price
tag,
it
is
a
complex
and
voluntary
process
that
ultimately
depends
on
the
experience
of
the
conducting
institution.
SciXess
®
voluntarily
binds
itself
to
follow
the
strong
principles
of
credit
rating
agencies
as
defined
in
the
IOSCO
’s
"Code
of
Conduct
Fundamentals
for
Credit
Rating
Agencies“
(International
Organization
of
Securities Commissions) to guarantee:
•
Independency,
•
Objectivity,
•
Credibility,
and
•
Disclosure
of the complete rating / valuation process.
SciXess’ Biotech Business Valuation & Technology Rating services are designed to:
•
Help the management team to better understand their strategic options
•
Support you in generating profit from innovative technologies
•
Support investment decisions
•
Create real added value on a cost effective basis
•
Be a highly qualified source for a second opinion
•
Provide an independent and objective platform of experts’ knowledge
•
Provide
relevant
information
about
the
market
and
the
competitive
environment of your technology or your (portfolio) company
•
Help you to achieve the best return on your investment
Consulting
Licensing
Rating
To
offer
our
clients
best
quality
company
ratings
,
SciXess
®
expanded
its
analytical
framework
through
a
close
collaboration
with
the
renowned
Rating-Services
AG
,
R@S
(Munich)
(since
2010
part
of
F@S,
Financial
Services
Ltd.,
London
–
Munich).
As
a
pioneer
in
the
rating
of
SMEs
throughout
all
industries,
as
well
as
funds
management
companies
(VC)
and
issuing
houses.
R@S
is
market
leader
and
reports
the
highest
number
of
ratings
of
small
and
medium-sized
enterprises.
Together
with
R@S,
sciXess
®
developed
the
“
Biotech
Business
Valuation
Tool
”,
an
evaluation
instrument
that
considers
the
characteristics
of
the
Biopharmaceutical
sector;
amongst
them
the
fact
that
R&D
costs
are
substantial
and
that
intellectual property is an important economic asset in this industry.
We make you
succeeed!
© sciXess
®
2002-2023
